Prospecto: information for the user
Entacapona Teva 200mg film-coated tablets
entacapona
Read this prospect carefully before starting to take this medicine, because it contains important information for you.
1.What Entacapona Teva is and for what it is used
2.What you need to know before starting to take Entacapona Teva
3.How to take Entacapona Teva
4.Possible adverse effects
5.Storage of Entacapona Teva
6.Contents of the package and additional information
Entacapona Teva tablets contain entacapone and are used in combination with levodopa to treat Parkinson's disease. Entacapona Teva helps levodopa in relieving symptoms of Parkinson's disease. Entacapona Teva has no effect in relieving symptoms of Parkinson's disease unless administered with levodopa.
Do not take Entacapona Teva:
Warnings and precautions
Consult your doctor or pharmacist before starting to take Entacapona Teva:
Inform your doctor if you or your family/caregiver notice that you are developing unusual desires or tendencies to behave in an unusual way in you or that you cannot resist the impulse, determination, or temptation to perform certain activities that may harm you or others. These behaviors are called impulse control disorders and may include excessive gambling, eating, or spending, and an abnormally elevated or excessive sexual impulse or concern about an increase in sexual thoughts or feelings.Your doctor may need to review your treatment.
As Entacapona Teva must be taken together with other medications containing levodopa, read also carefully the leaflet of these medications.
It may be necessary to adjust the doses of other medications to treat Parkinson's disease when starting to take Entacapona Teva. Follow the instructions as indicated by your doctor.
Neuroleptic Malignant Syndrome (NMS) is a rare but severe reaction to certain medications, and may appear especially when the treatment with Entacapona Teva and other medications for Parkinson's disease is suddenly stopped or reduced. For NMS characteristics see section 4 “Possible side effects”. Your doctor may advise you to gradually discontinue the treatment with Entacapona Teva and other medications for Parkinson's disease.
The use of Entacapona Teva together with levodopa may cause drowsiness and may cause you to fall asleep suddenly. If this happens, do not drive or operate tools or machinery (see section “Driving and operating machinery”).
Other medications and Entacapona Teva
Inform your doctor or pharmacist if you are taking or have recently taken or may need to take any other medication.In particular, inform your doctor if you are using any of the following medications:
Pregnancy, breastfeeding, and fertility
Do not take Entacapona Teva during pregnancy or if you are breastfeeding your baby.
If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
If you take Entacapona Teva together with levodopa, it may lower your blood pressure, making you feel dizzy or lightheaded. Be careful when driving or operating tools or machinery.
Additionally, if you take Entacapona Teva together with levodopa, it may cause you to feel very sleepy, or fall asleep suddenly.
Do not drive or operate machinery if you experience these side effects.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Entacapona Teva is taken with medications that contain levodopa (whether levodopa/carbidopa or levodopa/benserazide preparations). You may also use other medications to treat Parkinson's disease at the same time.
The recommended dose of Entacapona Teva is one 200 mg tablet with each dose of levodopa.The maximum recommended dose is 10 tablets per day, that is, 2,000 mg of Entacapona Teva.
If you are undergoing dialysis due to renal insufficiency, your doctor may instruct you to increase the time between doses.
Use in children and adolescents
The experience with Entacapona Teva in children under 18 years is limited. Therefore, it is not possible to recommend the use of Entacapona Teva in children.
If you take more Entacapona Teva than you should
In case of overdose, consult your doctor, pharmacist, or go to the nearest hospital immediately.
If you forget to take Entacapona Teva
If you forget to take the Entacapona Teva tablet with your levodopa dose, you should continue treatment by taking the next Entacapona Teva tablet with the next levodopa dose.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Entacapona Teva
Do not interrupt treatment with Entacapona Teva unless your doctor instructs you to do so.
When treatment is interrupted,it is possible that your doctor will need to adjust the dose of other medications to treat Parkinson's disease.Sudden interruption of treatment with Entacapona Teva andother medications to treat Parkinson's disease,may cause unwanted side effects.See section 2 “Warnings and precautions”.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Teva Entacapone may cause side effects, although not everyone will experience them.Side effects caused by Teva Entacapone are generally mild or moderate.
Some of these side effects are often due to an increase in the effects caused by levodopa treatment and are more frequent at the beginning of treatment. If you experience these side effects at the start of treatment with Teva Entacapone, you should contact your doctor, who may decide to adjust the levodopa dose.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Rare (may affect up to 1 in 100 people):
Uncommon (may affect up to 1 in 1,000 people):
Very rare (may affect up to 1 in 10,000 people):
Unknown (frequency cannot be estimated from available data):
When Teva Entacapone is administered at higher doses:
At doses of 1,400 to 2,000 mg per day, the following side effects are more frequent:
Other important side effects that may occur:
You may experience the following side effects:
Inform your doctor if you experience any of these behaviors; they will discuss how to manage or reduce these symptoms.
Reporting side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect that does not appear in this leaflet.You can also report them directlythrough thenational reporting systemincluded in theAppendix V*.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and on the blister pack label after EXP. The expiration date is the last day of the month indicated.
Norequires special storage conditions.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications you no longer need.By doing so, you will help protect the environment.
Composition of Entacapone Teva
- The other components aremicrocrystalline cellulose, povidone, pregelatinized starch and magnesium stearate
- The film coating containspoly(vinyl alcohol), talc, titanium dioxide (E171), macrogol, yellow iron oxide (E172), soy lecithin and red iron oxide (E172).
Appearance of the product and contents of the pack
Entacapone Teva 200mg film-coated tablets are light brown, biconvex, elliptical tablets of approximately18mmin length and10mmin width with the word “E200” engraved on one face of the tablet, and smooth on the other face.
Entacapone Teva is available in HDPE containers with polypropylene screw-top lids with desiccant containing 30, 60, 100 or 175film-coated tablets. Some pack sizes may only be marketed.
Marketing Authorization Holder and Responsible Person for Manufacturing
Marketing Authorization Holder
Teva B.V.
Swensweg 5
2031GA Haarlem
Netherlands
Responsible Person for Manufacturing
TEVAPharmaceutical Works Private Limited Company
Pallagi út 13,
4042 Debrecen,
Hungary
Pharmachemie B.V.
Swensweg 5,
2031 GA Haarlem,
Netherlands
Teva Czech Industries s.r.o.
Ostravska 29, c.p. 305,
74770 Opava-Komarov,
Czech Republic
Teva Operations Poland Sp.z.o.o
ul. Mogilska 80,
31-546, Krakow,
Poland
For any information regarding this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien Teva Pharma Belgium N.V./S.A. /AG Tel/Tél: +32 3 820 73 73 | Luxembourg/Luxemburg ratiopharm GmbH. Germany/Deutschland Tél/Tel: +49 731 402 02 |
Bulgaria Teva Pharmaceuticals S.R.L Tel: +359 2 489 95 85 | Hungary Teva GyógyszergyárZrt Tel.: +36 1 288 64 00 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +35319127700 |
Denmark Teva Denmark A/S Tlf: +45 44 98 55 11 | Netherlands Teva Nederland B.V. Tel: +31 800 0228400 |
Germany TEVA GmbH Tel: + 49 731 402 08 | Lithuania UABTeva Baltics Tel: +370 5 266 02 03 |
Estonia UAB Teva BalticsEstonia branch Tel: +372 661 0801 | Norway Teva Norway AS Tlf: +47 66 77 55 90 |
Greece Specifar Α.Β.Ε.Ε. Tel: +30 2118805000 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43/1970070 |
Spain Teva Pharma, S.L.U. Tel: +34 91 387 32 80 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel.: +(48) 22 345 93 00 |
France Teva Santé Tél: +33 1 55 91 7800 | Portugal Teva Pharma - Produtos Farmacêuticos Lda Tel: +351 21 476 75 50 |
Croatia Pliva Hrvatska d.o.o. Tel: +385 1 37 20 000 | Romania Teva Pharmaceuticals S.R.L Tel: +4021 230 65 24 |
Ireland Teva Pharmaceuticals Ireland Tel: +35319127700 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390 |
Iceland Teva FinlandOy Finland Phone: +358 20 180 5900 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +(421) 2 5726 7911 |
Italy Teva Italia S.r.l. Tel: +39 028917981 | Finland Teva FinlandOy Phone: +358 20 180 5900 |
Cyprus SpecifarΑ.Β.Ε.Ε. Greece Tel: +30 2118805000 | Sweden Teva Sweden AB Tel: +46 42 12 11 00 |
Latvia UAB Teva Balticsbranch in Latvia Tel: +371 67 784 980 | United Kingdom Teva UK Limited Tel:+44 1977 628 500 |
Last date of revision of this leaflet:MM/YYYY.
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.